Amanote Research
Register
Sign In
Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2001
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
F Hammes
L Ruiz
M Gitlin
S Snyder
Publisher
Elsevier BV